# ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
Canonical URL: https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial
Ticker: URGN
Company: UroGen Pharma
Source: UroGen Pharma
Published: 2026-05-13 12:00 EST
Original Source URL: https://investors.urogen.com
## Summary

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) --

## Article Body
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-02 12:00 EST — [UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution](https://biopharmsignal.com/news/URGN/urogen-announces-agreement-resolving-patent-litigation-relating-to-jelmytor-mitomycin-for-pyelocalyceal-solution) — Source: UroGen Pharma
- 2026-06-01 20:10 EST — [UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: UroGen Pharma
- 2026-05-15 12:00 EST — [UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC](https://biopharmsignal.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc) — Source: UroGen Pharma
- 2026-05-13 12:00 EST — [ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial](https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial) — Source: UroGen Pharma
- 2026-05-07 12:00 EST — [UroGen Pharma to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences) — Source: UroGen Pharma
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)